QR Kodea

A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for alpelisib

In this study, we delved into the safety profile of alpelisib, an FDA-approved treatment for hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer, and PIK3CA-Related Overgrowth Spectrum (PROS). Despite its approval, real-world, long-term safety data is lackin...

Deskribapen osoa

Gorde:
Egile Nagusiak: Yu Lin, Xinlei Zheng, Yan Chen, Qichun Nian, Li Lin, Maohua Chen
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Elsevier 2024-03-01
Saila:Heliyon
Gaiak:
Alpelisib
Adverse event
FAERS database
Disproportionality analysis
Pharmacovigilance
Sarrera elektronikoa:http://www.sciencedirect.com/science/article/pii/S2405844024035606
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak